• français
    • English
  • English 
    • français
    • English
  • Login
JavaScript is disabled for your browser. Some features of this site may not work without it.
BIRD Home

Browse

This CollectionBy Issue DateAuthorsTitlesSubjectsJournals BIRDResearch centres & CollectionsBy Issue DateAuthorsTitlesSubjectsJournals

My Account

Login

Statistics

View Usage Statistics

The refinement of the super generic concept: semantic challenge for product re-innovation?

Thumbnail
Date
2015
Dewey
Economie industrielle
Sujet
Innovations; Pharmaceutical industry; Industrie pharmaceutique; Generic drugs; Médicaments génériques
JEL code
L65; L15; I11
Journal issue
GaBI Journal
Volume
4
Number
1
Publication date
2015
Publisher
Pro Pharma Communications International
URI
https://basepub.dauphine.fr/handle/123456789/14843
Collections
  • LEDa : Publications
Metadata
Show full item record
Author
Barei, Fereshteh
Ross, Malcolm
Type
Article accepté pour publication ou publié
Abstract (EN)
Background: Uptake of super generic or hybrid pharmaceuticals has decelerated despite their important economic potential for the generic pharmaceutical industry. The aim of switching to these product portfolios was to enable product differentiation; however, these strategies are influenced by new semantic challenges, which have hampered the promotion of value-added pharmaceuticals or super generics in recent years. Objective: To investigate whether the use of the term ‘generic’ would reduce product liability in marketing super generic or hybrid pharmaceuticals, decrease the promotion of value-added super generic versions, or both. Methods: A literature review was conducted using MEDLINE, EMBASE, EBSCO and pharmaceutical websites to identify recent studies about super generics. Face-to-face semi-structured interviews were also conducted to evaluate the evolution in marketing super generics as an alternative product strategy for generic pharmaceutical manufacturers. Results: ‘Super generic’ as a strategic product option is still attractive but semantic challenges around these products may influence their marketing potential. Super generics are concomitant with high quality and innovation. The word ‘generic’ is avoided by some manufacturers and has been replaced by the term ‘new therapeutic entities’ or ‘improved therapeutics’ to create a new identity for super generic products.

  • Accueil Bibliothèque
  • Site de l'Université Paris-Dauphine
  • Contact
SCD Paris Dauphine - Place du Maréchal de Lattre de Tassigny 75775 Paris Cedex 16

 Content on this site is licensed under a Creative Commons 2.0 France (CC BY-NC-ND 2.0) license.